During cancer progression and treatment, multiple subclonal populations of tumour cells
compete with one another, with selective pressures leading to the emergence of …

The potential clinical utility of circulating tumor cells (CTCs) in the diagnosis and
management of cancer has drawn a lot of attention in the past 10 years. CTCs disseminate …

Growing evidence for intratumour heterogeneity informs us that single-site biopsies fall short
of revealing the complete genomic landscape of a tumour. With an expanding repertoire of …

The importance of early cancer diagnosis and improved cancer therapy has been clear for
years and has initiated worldwide research towards new possibilities in the care strategy of …

Purpose: Bcl-2 is a critical regulator of apoptosis that is overexpressed in the majority of
small cell lung cancers (SCLC). Nativoclax (ABT-263) is a potent and selective inhibitor of …

Since the completion of the first human genome sequence and the advent of next generation
sequencing technologies, remarkable progress has been made in understanding the …

Heparanase is the only mammalian enzyme that cleaves heparan sulphate, an important
component of the extracellular matrix. This leads to the remodelling of the extracellular …

Introduction: Epithelial circulating tumor cells (CTCs) are detectable in patients with non-
small cell lung cancer (NSCLC). However, epithelial to mesenchymal transition, a widely …

Circulating tumor cells (CTCs) are a major contributor of cancer metastases and hold a
promising prognostic significance in cancer detection. Performing functional and molecular …

Circulating tumor cell (CTC) number in metastatic cancer patients yields prognostic
information consistent with enhanced cell migration and invasion via loss of adhesion, a …